Official advice on the safety of rosiglitazone

The European Medicines Agency (EMEA) has advised that patients should not stop treatment with rosiglitazone, the diabetes drug, in response to a recent study suggesting the drug significantly increased the risk of myocardial infarction (MI).

The article, published in the New England Journal of Medicine, raised concerns about the safety of rosiglitazone (Diabetes drug may increase MI risk). However, the EMEA has stated that they were aware of many of the studies and they had been assessed by the agency's safety committee. As a result, the EU product information was updated in September 2006 with information about the risk of cardiac ischaemic events.

The EMEA point out that some of the studies discussed in the NEJM paper included patient who were not treated in line with the indication approved in the EU. The agency emphasise that prescribers should adhere to the restrictions for use in patients with cardiac disease as set out in the product information.

What do you think? Comment below or email us at  

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in